Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care July 2005 Martin Sipkoff	Support Grows for Establishing National Clinical Trial Registry Stakeholders are pushing for a national clinical trial registry, and efforts by UnitedHealth Group are in the forefront. Medical journals are setting hard and fast rules.
Pharmaceutical Executive June 1, 2005 Joanna Breitstein	Turn the Page Changes in ethics and expectations are driving the way pharma interacts with medical publishers.
BusinessWeek June 28, 2004 Amy Barrett	When Medicine And Money Don't Mix Do drugmakers have too much control over lab data?
Bio-IT World July 2005 Kevin Davies	Trial Registries on Trial A group of influential editors from some of the world's boutique medical journals begin enforcing a new policy that would bar drug companies from publishing clinical trial data unless those trials are registered in a suitable public database.
Salon.com August 18, 2000 Arthur Allen	Tainted alliances Are doctors shilling for drug companies?
Pharmaceutical Executive September 1, 2008 Melanie North	Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning.
Pharmaceutical Executive October 1, 2005 Lisa Grimes	Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction.
Pharmaceutical Executive November 1, 2013 Jill Wechsler	Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Pharmaceutical Executive November 1, 2008 Jill Wechsler	Resolving Conflicting Interests The Physician Payment Sunshine Act would require pharmaceutical and medical device companies to disclose payments of more than $500 to doctors.
Pharmaceutical Executive June 1, 2007 Dinh Nguyen	Clinical Trials Under Scrutiny Over the last few years, there has been a growing number of instances of misconduct in clinical research.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
Pharmaceutical Executive June 1, 2006 Jill Wechsler	Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
Reason Aug/Sep 2007 Kerry Howley	Dying for Lifesaving Drugs Will desperate patients destroy the pharmaceutical system that produces tomorrow's treatments?
Managed Care September 2005 Arthur Lazarus	Individual Wariness Needed To Spot Biased Drug Research Full and accurate disclosure of conflicts by researchers does not ensure the prevention of publication of articles that are misleading or otherwise biased. Impossible-to-enforce mandates won't work. Pharmacy directors and others must pose the right questions to the right people.
Pharmaceutical Executive February 1, 2011 Jill Wechsler	The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
CIO March 15, 2006 Allan Holmes	Rx for Risk As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances will get into the market.
Chemistry World September 30, 2014	Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
AskMen.com Richard Stevens	Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
Information Today October 4, 2004 Susanne Bjorner	A Tough Test for PhRMA's New Clinical Study Results Database The announcement the day before of a worldwide withdrawal of Merck & Co.'s popular arthritis and acute pain medication Vioxx, created a high-bar test that shows the holes in the new database concept.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
Science News October 21, 2006 Janet Raloff	A Salty Controversy over Sodium-and-Health Papers A public-interest group has raised a ruckus over salt-industry payments to the authors of a nutrition journal's package of articles on salt's influence on health.
Fast Company December 2009 Elizabeth Svoboda	Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas.
Salon.com August 18, 2000 Vera Hassner Sharav & Adil E. Shamoo	Lab rats Why do people who participate in clinical studies have fewer protections than animals?
Pharmaceutical Executive April 1, 2012 Jill Wechsler	Shortages and Sunshine Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.
Pharmaceutical Executive May 1, 2006	Thought Leader: Scientific Expression Litigation over Vioxx continues in the courts. But another battle -- between journal editors and a study's authors -- is unfolding on the pages of a top-tier medical journal.
Wired August 24, 2009 Steve Silberman	Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology.
BusinessWeek October 23, 2006 Arlene Weintraub	How The Journals Are Cracking Down With concerns about conflicts of interest on the rise, many medical journals are cracking down.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Reason October 2007 Ronald Bailey	Ties That Bind Considering that thousands of clinical trials are undertaken every year, it's reassuring that the pharmaceutical industry's critics can turn up only a few instances of bad behavior caused by financial conflicts of interest during the last two decades.
Searcher January 2002 Myer Kutz	The Scholars Rebellion Against Scholarly Publishing Practices: Varmus, Vitek, and Venting In the decades-long arguments over STM (scientific/technical/medical) journal publishing, mainly about subscription price increases and intellectual property and accessibility issues, one thing has changed in the last few years. Scholars have become involved...
Reason April 2004 Todd Seavey	Regulation for Dummies A book about the FDA.
The Motley Fool December 4, 2007 Brian Orelli	An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications.
Pharmaceutical Executive November 1, 2014	EMA -- a Pioneer Permanently At Bay Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.
Bio-IT World March 8, 2005 Mark D. Uehling	Is That a Target on Her Back? Q&A with Deborah Zarin, head of ClinicalTrials.gov, the matchmaking Web site for patients seeking to participate in federally sponsored clinical trials.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
Pharmaceutical Executive September 1, 2011 Richard Gliklich	The Power of Observation Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
Pharmaceutical Executive July 30, 2007 Louis A. Morris	Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages.
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.
The Motley Fool June 19, 2009 Brian Orelli	Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.